SciSparc (SPRC) EBITDA: History & Chart

SciSparc Ltd.(SPRC)

Biotechnology · Tel Aviv, TA

$4.33-0.03 (-0.69%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About SciSparc Ltd.

SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.

Tel Aviv, TA

3 employees

scisparc.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Oz Adler

View full financials

EBITDA

The latest quarterly EBITDA is $447.00 Thousand. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.

Q4 FY2025 (2025-12-31).

Depreciation|Operating Income|Net Income|Free Cash Flow|Income Statement

EBITDA

SPRC EBITDA

$447000.00

Reported quarterly EBITDA; no daily interpolation. Q4 FY2025 (2025-12-31): $447000.00.

+126.22% over 10Y

Current EBITDA

$447.00K

$447.00 Thousand

Q4 FY2025 · 2025-12-31

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly EBITDA History

Period	EBITDA	QoQ Growth	YoY Growth
Q4 FY2025Period end 2025-12-31	$447.00K	N/A	N/A
Q2 FY2025Period end 2025-06-30	−$8.96M	N/A	N/A
Q4 FY2024Period end 2024-12-31	−$10.58M	N/A	N/A
Q2 FY2024Period end 2024-06-30	$3.75M	N/A	N/A
Q4 FY2023Period end 2023-12-31	$4.07M	N/A	N/A
Q2 FY2023Period end 2023-06-30	−$2.70M	N/A	N/A
Q4 FY2022Period end 2022-12-31	−$3.35M	N/A	N/A
Q2 FY2022Period end 2022-06-30	−$4.79M	N/A	N/A
Q4 FY2021Period end 2021-12-31	−$3.11M	N/A	N/A
Q2 FY2021Period end 2021-06-30	−$2.63M	N/A	N/A
Q4 FY2020Period end 2020-12-31	−$957.00K	N/A	N/A
Q2 FY2020Period end 2020-06-30	−$1.43M	N/A	N/A
Q4 FY2019Period end 2019-12-31	−$2.02M	N/A	N/A
Q2 FY2019Period end 2019-06-30	$13.00K	N/A	N/A
Q4 FY2018Period end 2018-12-31	−$2.95M	N/A	N/A
Q2 FY2018Period end 2018-06-30	−$1.65M	N/A	N/A
Q4 FY2017Period end 2017-12-31	−$2.57M	N/A	N/A
Q2 FY2017Period end 2017-06-30	−$1.43M	N/A	N/A
Q4 FY2016Period end 2016-12-31	−$397.41K	N/A	N/A
Q2 FY2016Period end 2016-06-30	−$1.09M	N/A	N/A
Q2 FY2015Period end 2015-06-30	−$409.03K	N/A	N/A
Q4 FY2014Period end 2014-12-31	−$261.92K	N/A	N/A
Q2 FY2014Period end 2014-06-30	−$496.68K	N/A	N/A
Q4 FY2013Period end 2013-12-31	−$1.37M	N/A	N/A
Q2 FY2013Period end 2013-06-30	−$999.74K	N/A	N/A
Q4 FY2012Period end 2012-12-31	−$1.70M	N/A	N/A
Q2 FY2012Period end 2012-06-30	−$1.70M	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of December 31, 2025

EBITDA

SPRC EBITDA

Current EBITDA

QoQ Growth

Historical Data

Quarterly EBITDA History

Related Metrics